MaaT013

Phase 3Small molecule

MMaaT Pharma

MaaT013 is one of 57 small molecule programs targeting Graft Versus Host Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Graft Versus Host DiseaseActive, not recruiting

RefractoryActive, not recruiting

Graft Versus Host DiseasePreclinical

Active, not recruiting

RefractoryPhase 3

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Graft Versus Host Disease

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Approved

15 2

Neoral

Novartis

Approved

9 3

Medrol

Pfizer

Approved

4 4

Selzentry

GSK

Approved

1 5

Gleevec

Olumiant

Nipent

Defitelio

Qvar

3 10

Cellcept

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Melanoma1 trial

Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04988841·70 enrolled

Refractory1 trial

MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

Active, not recruiting·MMaaT Pharma·Phase 3·NCT04769895·66 enrolled

Graft Versus Host Disease1 trial

Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease

Available·MMaaT Pharma··NCT04768907

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for MaaT013. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MaaT013 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MaaT013. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MaaT Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMaaT Pharma

MaaT013

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Melanoma1 trial

Refractory1 trial

Graft Versus Host Disease1 trial

References

Drug Info

Quick Facts

Related News